Skip to Content
Merck
All Photos(1)

Key Documents

SML3317

Sigma-Aldrich

Losartan

≥98% (HPLC), powder, angiotensin II receptor type 1 (AT1) antagonist

Synonym(s):

1-[1-[[2′-(2H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-butyl-4-chloro-1H-imidazol-5-yl]methanol, 2-Butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol, 2-Butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol, DUP 89

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H23ClN6O
CAS Number:
Molecular Weight:
422.91
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Losartan, ≥98% (HPLC)

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2

InChI

1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)

InChI key

PSIFNNKUMBGKDQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Losartan is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan is used for treatment of hypertension.

Pictograms

Health hazardExclamation mark

Signal Word

Danger

Hazard Statements

Hazard Classifications

Lact. - Repr. 1B - Skin Sens. 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoon-A Park et al.
Journal of personalized medicine, 11(7) (2021-07-03)
This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used
Daniel P Regan et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(4), 662-676 (2021-09-29)
There is increasing recognition that progress in immuno-oncology could be accelerated by evaluating immune-based therapies in dogs with spontaneous cancers. Osteosarcoma (OS) is one tumor for which limited clinical benefit has been observed with the use of immune checkpoint inhibitors.
P C Wong et al.
The Journal of pharmacology and experimental therapeutics, 255(2), 584-592 (1990-11-01)
DuP 753 and PD123177 are two nonpeptide angiotensin II (AII)-specific ligands, which show high affinities for two respective and distinct subtypes of AII binding sites, i.e., AII-1 and AII-2 sites, respectively, in the rat adrenal gland, brain and uterus. The

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service